Hypervision Surgical Joins Tech Nation's Upscale 2026 Cohort
Hypervision Surgical has been selected for Upscale 2026, Tech Nation’s growth programme for the UK’s most ambitious post-Series A scaleups.
Read more

Hypervision Surgical Ltd is a spin-out company formed from King's College London and was founded by a team of clinicians, medical imaging and artificial intelligence (AI) experts. Based on safe light alone, our goal is to equip clinicians with advanced computer-assisted tissue analysis for improved surgical precision and patient safety.
Better intraoperative guidance can help reduce patient morbidity and healthcare costs across surgical specialties. For example, brain tumour patients undergoing surgery have significantly improved outcomes and increased life expectancy if complete tumour removal is achieved. However, maximal resection needs to be balanced with the goal of healthy tissue preservation in order to minimise patient risk and neurological impairment. Yet, even with the most advanced current techniques, intraoperative decisions with potentially life-changing consequences are still based on the surgeon’s subjective visual assessment.
Detailed real-time information increases surgical precision and patient safety
Intraoperative assessment requires a scale compatible with surgical action
Surgical workflow benefits from non-contact measurement approaches
Independence of exogenous contrast agents prevents side effects
Our approach is non-contact, non-invasive and does not require any exogenous contrast agent. We rely on the safe application of light alone.
Using AI, we provide quantitative, wide-field information on physiological tissue properties including perfusion assessment of tissue and blood vessels.
Our system is capable of AI-driven, wide-field tissue differentiation to identify tumour, normal tissue, nerves and blood vessels – in real time.
Hyperspectral imaging is a safe, non-contact and non-invasive optical imaging modality perfectly suited for the clinic. By splitting light into multiple spectral bands far beyond the conventional red/green/blue colours that the naked eye can see, hyperspectral imaging carries diagnostic information about tissue properties ideal for objective tissue characterisation.
With our strong expertise in interventional imaging, AI and medical devices, we have designed an intraoperative imaging system that seamlessly integrates into the surgical workflow and is capable of wide-field real-time data-driven tissue characterisation. This will objectively enhance the surgeon's ability to visualise and characterise tissue intraoperatively without injecting any contrast agents. In addition, we can monitor vital physiological tissue properties thereby increasing surgical precision and patient safety while optimising resection.
Further clinical studies are scheduled to develop and evaluate our technology to achieve commercial readiness.
Hypervision Surgical has been selected for Upscale 2026, Tech Nation’s growth programme for the UK’s most ambitious post-Series A scaleups.
Read moreHypervision Surgical has attained certification to ISO/IEC 27001:2022 and ISO/IEC 27701:2019, the international standards for information security management and privacy information management.
Read moreHypervision, a pioneer in real-time hyperspectral imaging for surgery, announced the successful closing of its oversubscribed £17m Series A financing round, led by Heal Capital with participation from Angelini Ventures, IP Group, and Daycrest.
Read moreAt Hypervision Surgical, we are always looking for ambitious and passionate people who want to help shape the future of surgery. Visit our careers page to discover current opportunities. Don’t see a role that fits? We’d still love to hear from you – get in touch.